PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess the relative bioavailability of RBP-7000 formulated with 2
different molecular weights (MW) (low and high MW as test treatments) of poly
(DL-lactide-co-glycolide) with a carboxylic acid end group (PLGH) polymer compared to
intermediate MW PLGH polymer following single subcutaneous (SC) injection of RBP-7000 in
subjects with stable schizophrenia.
Secondary Objective:
To evaluate the safety and tolerability of single SC injections of RBP-7000 using a PLGH
polymer of 2 different MW (low and high MW as test treatments) compared to intermediate MW
polymer in subjects with stable schizophrenia.